TEVA-BUPRENORPHINE/NALOXONE TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE); NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE)

متاح من:

TEVA CANADA LIMITED

ATC رمز:

N07BC51

INN (الاسم الدولي):

BUPRENORPHINE, COMBINATIONS

جرعة:

8MG; 2MG

الشكل الصيدلاني:

TABLET

تركيب:

BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2MG

طريقة التعاطي:

SUBLINGUAL

الوحدات في الحزمة:

30

نوع الوصفة الطبية :

Narcotic (CDSA I)

المجال العلاجي:

OPIATE PARTIAL AGONISTS

ملخص المنتج:

Active ingredient group (AIG) number: 0252216002; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2019-12-17

خصائص المنتج

TEVA-BUPRENORPHINE/NALOXONE
_ _
_Page 1 of 65_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N TEVA-BUPRENORPHINE/NALOXONE
Buprenorphine and Naloxone Sublingual Tablets
Tablets, Buprenorphine (as Buprenorphine Hydrochloride) and Naloxone
(as
Naloxone Hydrochloride Dihydrate),
2 mg/0.5 mg and 8 mg/2 mg, sublingual
Teva Standard
Partial Opioid Agonist
and
Opioid Antagonist
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9
www.tevacanada.com
Date of Initial Authorization:
April 18, 2016
Date of Revision:
January 25, 2022
Submission Control No.: 254725
_ _
TEVA-BUPRENORPHINE/NALOXONE
_ _
_Page 2 of 65_
RECENT MAJOR LABEL CHANGES
3 Serious Warning and Precautions
01/2022
4 Dosage and Administration
01/2022
7 Warning and Precautions
01/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
P
EDIATRICS
....................................................................................................................................................
4
1.2
G
ERIATRICS
...................................................................................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................. 5
4
DOSAGE AND ADMINISTRATION
.....................................................................